Full metadata record

DC Field Value Language
dc.contributor.authorKim, Hee Jin-
dc.contributor.authorJung, Myung-Ho-
dc.contributor.authorKim, Hwan-
dc.contributor.authorEl-Gamal, Mohammed I.-
dc.contributor.authorSim, Tae Bo-
dc.contributor.authorLee, So Ha-
dc.contributor.authorHong, Jun Hee-
dc.contributor.authorHah, Jung-Mi-
dc.contributor.authorCho, Jung-Hyuck-
dc.contributor.authorChoi, Jung Hoon-
dc.contributor.authorYoo, Kyung Ho-
dc.contributor.authorOh, Chang-Hyun-
dc.date.accessioned2024-01-20T20:02:20Z-
dc.date.available2024-01-20T20:02:20Z-
dc.date.created2021-09-02-
dc.date.issued2010-01-01-
dc.identifier.issn0960-894X-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/131793-
dc.description.abstractSynthesis of a new series of diarylureas and amides having pyrrolo[3,2-b]pyridine scaffold is described. Their in vitro antiproliferative activity against human melanoma cell line A375 and HS 27 human fibroblast cell line was tested and the effect of substituents on the pyrrolo[3,2-b]pyridine was investigated. The newly synthesized compounds, except meta-substituted derivatives (Ij-k and Iv-w), generally showed superior or similar activity against A375 to Sorafenib. Among all of these derivatives, compounds Ir and It having 5-benzylamide substituted 4'-amide moieties showed the most potent antiproliferative activity against A375. (C) 2009 Published by Elsevier Ltd.-
dc.languageEnglish-
dc.publisherPergamon Press Ltd.-
dc.subjectREFRACTORY SOLID TUMORS-
dc.subjectFACTOR RECEPTOR INHIBITOR-
dc.subjectRAF KINASE-
dc.subjectSUBSTITUTED UREAS-
dc.subjectPHASE-I-
dc.subjectBAY-43-9006-
dc.subjectTHERAPY-
dc.subjectPHARMACOKINETICS-
dc.subjectINTERLEUKIN-2-
dc.subjectPATHWAY-
dc.titleSynthesis and antiproliferative activity of pyrrolo[3,2-b]pyridine derivatives against melanoma-
dc.typeArticle-
dc.identifier.doi10.1016/j.bmcl.2009.08.005-
dc.description.journalClass1-
dc.identifier.bibliographicCitationBioorganic & Medicinal Chemistry Letters, v.20, no.1, pp.413 - 417-
dc.citation.titleBioorganic & Medicinal Chemistry Letters-
dc.citation.volume20-
dc.citation.number1-
dc.citation.startPage413-
dc.citation.endPage417-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000272935600093-
dc.identifier.scopusid2-s2.0-72049089544-
dc.relation.journalWebOfScienceCategoryChemistry, Medicinal-
dc.relation.journalWebOfScienceCategoryChemistry, Organic-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.relation.journalResearchAreaChemistry-
dc.type.docTypeArticle-
dc.subject.keywordPlusREFRACTORY SOLID TUMORS-
dc.subject.keywordPlusFACTOR RECEPTOR INHIBITOR-
dc.subject.keywordPlusRAF KINASE-
dc.subject.keywordPlusSUBSTITUTED UREAS-
dc.subject.keywordPlusPHASE-I-
dc.subject.keywordPlusBAY-43-9006-
dc.subject.keywordPlusTHERAPY-
dc.subject.keywordPlusPHARMACOKINETICS-
dc.subject.keywordPlusINTERLEUKIN-2-
dc.subject.keywordPlusPATHWAY-
dc.subject.keywordAuthorPyrrolo[3,2-b]pyridine-
dc.subject.keywordAuthorA375-
dc.subject.keywordAuthorHS 27-
dc.subject.keywordAuthorAntiproliferative activity-
dc.subject.keywordAuthorMelanoma-
Appears in Collections:
KIST Article > 2010
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE